These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 30171992)

  • 21. Effects of CBD-Enriched
    Fleury-Teixeira P; Caixeta FV; Ramires da Silva LC; Brasil-Neto JP; Malcher-Lopes R
    Front Neurol; 2019; 10():1145. PubMed ID: 31736860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature.
    Bilge S; Ekici B
    J Cannabis Res; 2021 Dec; 3(1):53. PubMed ID: 34911567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Updates in Psychopharmacology for the Core and Associated Symptoms of Autism Spectrum Disorder.
    Thom RP; Pereira JA; Sipsock D; McDougle CJ
    Curr Psychiatry Rep; 2021 Oct; 23(12):79. PubMed ID: 34643815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychotropic Medication Use for Adults with Autism Spectrum Disorder who Receive Services and Supports Through Adult Developmental Disability Services in the United States.
    Esler A; Hewitt A; Hall-Lande J; Pettingell SL; Houseworth J
    J Autism Dev Disord; 2019 Jun; 49(6):2291-2303. PubMed ID: 30706350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retracing our steps: A review on autism research in children, its limitation and impending pharmacological interventions.
    Salloum-Asfar S; Zawia N; Abdulla SA
    Pharmacol Ther; 2024 Jan; 253():108564. PubMed ID: 38008401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cannabinoid treatment for autism: a proof-of-concept randomized trial.
    Aran A; Harel M; Cassuto H; Polyansky L; Schnapp A; Wattad N; Shmueli D; Golan D; Castellanos FX
    Mol Autism; 2021 Feb; 12(1):6. PubMed ID: 33536055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder.
    Wake R; Miyaoka T; Furuya M; Hashioka S; Horiguchi J
    CNS Neurol Disord Drug Targets; 2016; 15(5):551-63. PubMed ID: 27071791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan.
    Mizuguchi M; Ikeda H; Kagitani-Shimono K; Yoshinaga H; Suzuki Y; Aoki M; Endo M; Yonemura M; Kubota M
    Brain Dev; 2019 Jan; 41(1):1-10. PubMed ID: 30060984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents.
    Stepanova E; Dowling S; Phelps M; Findling RL
    Dialogues Clin Neurosci; 2017 Dec; 19(4):395-402. PubMed ID: 29398934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on pharmacotherapy of autism spectrum disorder in children and adolescents.
    Goel R; Hong JS; Findling RL; Ji NY
    Int Rev Psychiatry; 2018 Feb; 30(1):78-95. PubMed ID: 29693461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The therapeutic role of Cannabidiol in mental health: a systematic review.
    Khan R; Naveed S; Mian N; Fida A; Raafey MA; Aedma KK
    J Cannabis Res; 2020 Jan; 2(1):2. PubMed ID: 33526132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapy for the treatment of aggression in pediatric and adolescent patients with autism spectrum disorder comorbid with attention-deficit hyperactivity disorder: A questionnaire survey of 571 psychiatrists.
    Yamamuro K; Tsujii N; Ota T; Kishimoto T; Iida J
    Psychiatry Clin Neurosci; 2017 Aug; 71(8):554-561. PubMed ID: 28317224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mood Stabilizers in Children and Adolescents With Autism Spectrum Disorders.
    Canitano R
    Clin Neuropharmacol; 2015; 38(5):177-82. PubMed ID: 26366961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current state of evidence of cannabis utilization for treatment of autism spectrum disorders.
    Agarwal R; Burke SL; Maddux M
    BMC Psychiatry; 2019 Oct; 19(1):328. PubMed ID: 31664964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment.
    Premoli M; Aria F; Bonini SA; Maccarinelli G; Gianoncelli A; Pina SD; Tambaro S; Memo M; Mastinu A
    Life Sci; 2019 May; 224():120-127. PubMed ID: 30910646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxytocin and Autism Spectrum Disorders.
    Yamasue H; Domes G
    Curr Top Behav Neurosci; 2018; 35():449-465. PubMed ID: 28766270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Utility of Cannabidiol in the Treatment of Refractory Epilepsy.
    Reddy DS
    Clin Pharmacol Ther; 2017 Feb; 101(2):182-184. PubMed ID: 27506704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities.
    Barchel D; Stolar O; De-Haan T; Ziv-Baran T; Saban N; Fuchs DO; Koren G; Berkovitch M
    Front Pharmacol; 2018; 9():1521. PubMed ID: 30687090
    [No Abstract]   [Full Text] [Related]  

  • 40. Cannabidiol and cannabis-inspired terpene blends have acute prosocial effects in the BTBR mouse model of autism spectrum disorder.
    Staben J; Koch M; Reid K; Muckerheide J; Gilman L; McGuinness F; Kiesser S; Oswald IWH; Koby KA; Martin TJ; Kaplan JS
    Front Neurosci; 2023; 17():1185737. PubMed ID: 37397463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.